Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11460118 | 0.79 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL4424974 | 0.77 | KDM4E (0.46) | KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL19154594 | 0.74 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL30194782 | 0.74 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL27868088 | 0.74 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL16433009 | 0.73 | KDM4E (0.45) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL11013731 | 0.69 | PDXK (0.41) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL21259071 | 0.68 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL21259077 | 0.68 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL3442728 | 0.68 | KDM4E (0.38) | KDM4EALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20090191131-A1 | USE OF PARTICULATE CONTRAST AGENTS IN DIAGNOSTIC IMAGING FOR STUDYING PHYSIOLOGICAL PARAMATERS | FOSSHEIM SIGRID LISE | 2009-07-30 | — | — | US | disclosed |
| US-20070231260-A1 | Transporter-targeted methods of diagnosis and treatment | XENOPORT, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007041268-A2 | TRANSPORTER-TARGETED METHODS OF DIAGNOSIS AND TREATMENT | XENOPORT, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20050136002-A1 | Use of particulate contrast agents in diagnostic imaging for studying physiological paramaters | GE HEALTHCARE AS (NO) | 2005-06-23 | — | — | US | disclosed |
| EP-1069888-B1 | USE OF PARTICULATE CONTRAST AGENTS IN DIAGNOSTIC IMAGING FOR STUDYING PHYSIOLOGICAL PARAMETERS | AMERSHAM HEALTH AS (NO) | 2004-09-22 | — | — | EP | disclosed |
| EP-1069888-A1 | USE OF PARTICULATE CONTRAST AGENTS IN DIAGNOSTIC IMAGING FOR STUDYING PHYSIOLOGICAL PARAMETERS | NYCOMED IMAGING AS (NO) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999052505-A1 | USE OF PARTICULATE CONTRAST AGENTS IN DIAGNOSTIC IMAGING FOR STUDYING PHYSIOLOGICAL PARAMETERS | NYCOMED IMAGING A.S. (NO) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | KDM4E 2279/4885ALDH1A1 920/4885HPGD 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.